Temporal trends in characteristics of patients undergoing transcatheter tricuspid edge-to-edge repair for tricuspid regurgitation

Karl-Patrik Kresoja¹^,², MD; Lukas Stolz³, MD; Anne Schöber¹^,², MD; KarlPhilipp Rommel², MD; Sebastian Rosch¹^,², MD; Florian Schlotter², MD; Muhammed Gerçek⁴, MD; Christoph Pauschinger⁵^,⁶, MD; Wolfgang Rottbauer⁷, MD; Mohammad Kassar⁸, MD; Bjoern Goebel⁹, MD; Paolo Denti¹⁰, MD; Tienush Rassaf¹¹, MD; Manuel Barreiro-Perez¹², MD; Peter Boekstegers¹³, MD; Monika Zdanyte¹⁴, MD; Marianna Adamo¹⁵, MD; Flavien Vincent¹⁶, MD, PhD; Philipp Schlegel¹⁷, MD; Ralph-Stephan von Bardeleben¹, MD; Mirjam G. Wild¹⁸, MD; Stefan Toggweiler¹⁹, MD; Mathias H. Konstandin¹⁷, MD; Eric Van Belle¹⁶, MD, PhD; Marco Metra¹⁵, MD; Tobias Geisler¹⁴, MD; Rodrigo Estévez-Loureiro¹², MD; Peter Luedike¹¹, MD; Francesco Maisano¹⁰, MD; Philipp Lauten⁹, MD; Fabien Praz⁸, MD; Mirjam Kessler⁷, MD; Andreas Ruck²⁰, MD; Daniel Kalbacher⁵^,⁶, MD; Volker Rudolph⁴, MD; Christos Iliadis²¹, MD; Holger Thiele³, MD; Jörg Hausleiter³^,²², MD; Philipp Lurz¹, MD, PhD; on behalf of the EuroTR investigators

1. Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; 2. Department of Cardiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany; 3. Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany; 4. Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany; 5. Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany; 6. German Center of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany; 7. Department of Cardiology, Ulm University Hospital, Ulm, Germany; 8. Department of Cardiology, Inselspital Bern, Bern University Hospital, Bern, Switzerland; 9. Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Bad Berka, Germany; 10. Heart Valve Center, Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy; 11. Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; 12. Hospital Álvaro Cunqueiro, Vigo, Spain; 13. Department of Cardiology, Helios Klinikum Siegburg, Siegburg, Germany; 14. Medical Clinic III, University Hospital Tübingen, Tübingen, Germany; 15. ASST Spedali Civili di Brescia, Brescia, Italy and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy; 16. Cardiology Department, Centre Hospitalier Universitaire de Lille, Lille, France; 17. Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg, Germany; 18. University Heart Center Freiburg/Bad Krozingen, Bad Krozingen, Germany; 19. Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland; 20. Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden; 21. Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany; 22. German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany

In the last decade, the management of tricuspid regurgitation (TR) has significantly changed owing to the emergence of novel interventional treatment approaches that have allowed safe and effective treatment of TR. While retrospective studies suggested a survival benefit of interventional TR treatment as compared to patients treated conservatively12, the first randomised clinical trial that compared tricuspid transcatheter edge-to-edge repair (T-TEER) to optimal medical treatment, the TRILUMINATE Pivotal Trial, showed no differences at 1 year with regards to mortality or heart failure hospitalisation, albeit meeting its primary endpoint3. A possible explanation for this discrepancy might be attributable to a change in the characteristics of patients who are referred for T-TEER therapy nowadays, as compared to initial treatment experiences. Therefore, the aim of this study was to evaluate changes in the characteristics of patients referred for T-TEER and investigate their influence on outcomes.

Patients from the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR) who underwent interventional therapy for symptomatic TR from 2016 until 2022 at 12 European study sites (Germany, Italy, Switzerland, Spain, France, and Sweden) were...

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com